Tricyclic nucleosides and oligomeric compounds prepared therefrom

Abstract

The present invention provides novel tricyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the tricyclic nucleosides into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. Such oligomeric compounds can also be included in double stranded compositions. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

What is claimed is: 
     
         1 . A tricyclic nucleoside described by general Formula I: 
       
         
           
           
               
               
           
         
       
       wherein:
 Bx is heterocyclic base moiety; 
 one of T 1  and T 2  is hydroxyl (—OH) or a protected hydroxyl and the other of T 1  and T 2  is a phosphate or a reactive phosphorus group; 
 q 1  and q 2  are each, independently, H, F or Cl, 
 at least one of q 3 , q 4  and q 5  is, independently, a group described by a general formula —A 1 -X h -A 2 -Y n , wherein
 A 1  is a C k -alkyl, C k -alkenyl or C 1 -alkynyl, with k being an integer selected from the range of 0 to 20, 
 X h  is —C(═O)—, —C(═O)NR—, —O—, —O—, —S—, —NR—, —C(═O)R, —C(═O)OR, C(═O)NR 2 —, —OR, —SR or —NR 2 , with each R being selected independently from H, methyl, ethyl, propyl, butyl, acetyl and 2-hydroxyethyl, and h is 0 or 1, 
 A 2  is a C i -alkyl, C i -alkenyl or C i -alkynyl, with i being an integer selected from the range of 0 to 20, 
 Y is a substituent group attached to any carbon atom on A 1  and/or A 2 , selected from —F, —Cl, —Br, ═O, —OR, —SR, —NR 2 , —NR 3   + , NHC(═NH)NH 2 , —CN, —NC, —NCO, —NCS, —SCN, —COR, —CO 2 R, CONR 2 , —R, with each R being selected independently from H, methyl, ethyl, propyl, butyl, acetyl and 2-hydroxyethyl, and n is 0, 1, 2, 3, 4, 5 or 6, 
 wherein k+i equals at least 1, 
 the other ones of q 3 , q 4  and q 5  are, independently, H, F or Cl, 
 
 one of z 1  and z 2  is H, —OH, F, Cl, OCH 3 , OCF 3 , OCH 2 CH 3 , OCH 2 CF 3 , OCH 2 -CH═CH 2 , O(CH 2 ) 2 -OCH 3 , O(CH 2 ) 2 -O(CH 2 ) 2 -N(CH 3 ) 2 OCH 2 C(═O) —N(H)CH 3 , OCH 2 C(═O)—N(H)—(CH 2 ) 2 -N(CH 3 ) 2  or OCH 2 -N(H)—C(═NH)NH 2 . 
 
     
     
         2 . The tricyclic nucleoside of  claim 1 , wherein Bx is uracil, thymine, cytosine, 5-methyl-cytosine, adenine or guanine. 
     
     
         3 . The tricyclic nucleoside of any one of the preceding claims, wherein T 1  is hydroxyl or protected hyroxyl, and wherein T 2  is a reactive phosphorus group selected from an H-phosphonate or a phosphoramidite. 
     
     
         4 . The tricyclic nucleoside of any one of the preceding claims, wherein T 4  is 4,4′-dimethoxytrityl and T 2  is diisopropylcyanoethoxy phosphoramidite or a controlled pore glass surface. 
     
     
         5 . The tricyclic nucleoside of any one of the preceding claims, wherein q 3  is described by the general formula —A 1 X h -A 2 -Y n , and q 4  and q 5 , independently of each other, are H, F or Cl. 
     
     
         6 . The tricyclic nucleoside of any one of the preceding claims, wherein k is an interger from 3 to 16, h is 0, i is 0 and n is 1, 2, or 3. 
     
     
         7 . The tricyclic nucleoside of any one of the preceding  claims 1  to  5 , wherein k is 1, h is 1 and X is —O—, COO—, CONH— or CONR—, i is an integer from 3 to 16 and n is 1, 2, or 3. 
     
     
         8 . The tricyclic nucleoside of any one of the preceding  claims 6  to  7 , wherein n is 1 and Y is selected from NH 2 , NHR, NR 2 , NR 3   +  and NHC(═NH)NH 2 , with R having the meaning defined above. 
     
     
         9 . The nucleoside of  claim 8 , wherein Y is in the ω-position. 
     
     
         10 . The tricyclic nucleoside of any one of the preceding claims, wherein the sum of i+k is an integer from 3 to 16, particularly from 3 to 12, more particularly from 5 to 10. 
     
     
         11 . The tricyclic nucleoside of any one of preceding claims, wherein A 1  is CH 2 , h is 1 and X h  is —C(═O)O—, C(═O)NH—, and A 2  is a C2 to C16 alkyl, Y n  is NH 2  and n is 0 or 1. 
     
     
         12 . The tricyclic nucleoside of  claim 1 , wherein A 1  is CH 2 . 
     
     
         13 . The tricyclic nucleoside of  claim 1 , wherein k is 0. 
     
     
         14 . A tricyclic nucleoside selected from the group of 
       
         
           
           
               
               
           
         
       
       wherein Bx is selected from uracil, thymine, cytosine, 5-methylcytosine, adenine and guanine. 
     
     
         15 . An oligomeric compound comprising at least one tricyclic nucleoside according to any one of  claims 1  to  0 , wherein said oligomeric compound comprises from 8 to 40 monomeric subunits. 
     
     
         16 . The oligomeric compound of  claim 15 , wherein each Bx is, independently, uracil, thymine, cytosine, 5-methylcytosine, adenine or guanine. 
     
     
         17 . The oligomeric compound of any one of  claims 15  to  16 , wherein each internucleoside linking group is, independently, a phosphodiester internucleoside linking group or a phosphorothioate internucleoside linking group. 
     
     
         18 . The oligomeric compound of any one of  claims 15  to  17 , comprising a first region having at least two contiguous tricyclic nucleosides having Formula II. 
     
     
         19 . The oligomeric compound of  claim 18  comprising a second region having at least two contiguous monomeric subunits wherein each monomeric subunit in the second region is a modified nucleoside different from the tricyclic nucleosides of Formula II of said first region. 
     
     
         20 . The oligomeric compound of  claim 19  further comprising a third region located between said first and second regions wherein each monomer subunit in the third region is independently, a nucleoside or a modified nucleoside that is different from each tricyclic nucleoside of Formula II of the first region and each monomer subunit of the second region. 
     
     
         21 . The oligomeric compound of any one of  claims 15  to  20  comprising a gaped oligomeric compound having an internal region of from 6 to 14 contiguous monomer subunits flanked on each side by an external region of from 1 to 5 contiguous monomer subunits wherein each monomer subunit in each external region is a tricyclic nucleoside of Formula II and each monomer subunit in the internal region is, independently, a nucleoside or a modified nucleoside. 
     
     
         22 . The oligomeric compound of any one of  claims 15  to  21 , comprising one or several nucleotide blocks selected from 
       
         
           
           
               
               
           
         
         wherein T 3  and T 4  have the meanings outlined above. Use of a trycyclic nucleoside according to any of  claims 1  to  0  in the method for solid-phase synthesis of an oligonucleotide.